

Full Length Research Paper

Cytotoxic activities of *Coriolus versicolor* (Yunzhi) extracts on human liver cancer and breast cancer cell line

Xuanwei Zhou^{1*}, Hua Jiang², Juan Lin² and Kexuan Tang¹

¹Plant Biotechnology Research Center, School of Agriculture and Biology, Fudan-SJTU-Nottingham, Plant Biotechnology R and D Center, Shanghai Jiao Tong University, Shanghai 200030, China.

²State Key Laboratory of Genetic Engineering, School of Life Sciences, Fudan-SJTU-Nottingham, Plant Biotechnology R and D Center, Morgan-Tan International Center for Life Sciences, Fudan University, Shanghai 200433, P. R. China.

Accepted 1 March, 2007

The CVP (*Coriolus versicolor* polysaccharide) is well known as anti-tumor drug in clinical applications. Although recent studies have demonstrated that CVP can inhibit the proliferation of cancer cells *in vitro* and *in vivo*, the different purity level of CVP has a different affect on various cancer cells. In this study, the crude CVP was extracted from *C. versicolor* dry fruit bodies by hot-water extraction and ethanol precipitation. The content of CVP was 7.74% in the fruit bodies, while 54.69% in the crude extracts by phenol-vitriolic colorimetry. After that, the *in vitro* cytotoxic activities of the CVP were examined on the four human liver cancer (7703, HepG2, 7721, PLC) and four human breast cancer (Bcap37, ZR75-30, MCF-7, T-47D) cell lines using a MTT cytotoxicity assay. The results showed that the CVP inhibited the proliferation of 7703, Bcap37, T-47D in low concentration; the IC₅₀ values on 7703, Bcap37 and T-47D were 18.37, 14.42 and 9.29 mg/l, respectively. The CVP also inhibited the proliferation of MCF-7 and ZR75-30, but at high concentration, the IC₅₀ values on MCF-7 and ZR75-30 were 39.26 and 34.59 mg/l, respectively. The CVP does not inhibit the proliferation of HepG2, 7721, PLC and human normal liver cell line (WRL). The CVP was found to selectively inhibit the proliferation of human liver cancer and human breast cancer.

Key words: *Coriolus versicolor*, fruit body, polysaccharide, anti-tumor.

INTRODUCTION

Coriolus versicolor, also known as Yun Zhi (YZ), belonging to the family Basidiomycotina, is a mushroom widely used in traditional Chinese herbal remedies. Its medical value correlate to *C. versicolor* extracts. Of the *C. versicolor*-derived therapeutics extracts, polysaccharopeptides are commercially the best established. The

polysaccharopeptides were obtained from *C. versicolor* known as *C. versicolor* polysaccharides (CVP), is a complicated protein-bound polysaccharide extracted from its mycelium or fruiting body. The composition of the polysaccharopeptide appears to depend on the source of the material and the method of recovery used, such as polysaccharopeptide Krestin (PSK) obtained from the extraction of *C. versicolor* (CM-101) strains in China and polysaccharopeptide (PSP) obtained from the extraction of *C. versicolor* (Cov-1) strains in Japan. Both products have similar physiological activities but are structurally different (Chu et al., 2002). The major bioactive CVP is a β -(1 \rightarrow 3)-glucan branching at 4' and 6' positions. The CVP mainly consists of neutral polysaccharides of glu-

*Corresponding author. E-mail: xuanweizhou@sjtu.edu.cn. Tel: +86-21-62932002. Fax: +86-21- 65643552.

Abbreviations: YZ, Yun Zhi; CVP, *Coriolus versicolor* polysaccharides; PSK, polysaccharopeptide Krestin; PSP, polysaccharopeptide; and MTT, 3-(4, 5-dimethylthiazolyl)-2, 5-diphenyl- tetrazolium bromide.

cose units; the main chain of β -1-3 consisted of β -D-1, 4-Glc and β -D-1, 3-Glc, and branch chains were situated, β -D-1, 3, 6-Glc and β -D-1, 4, 6-Glc (Zhang et al., 2001). The substance contained a branched glucan core with (1 \rightarrow 3)- β -, (1 \rightarrow 4)- β - and/or (1 \rightarrow 6)- β -linkages, has a molecular weight of about 100 kDa and is highly water-soluble (Ng, 1998; Wang et al., 1996).

The CVP have many pharmacological activities, including immunopotential, immunosuppressive, improvement of appetite and liver function, calming of the central nervous system and enhancement of pain threshold. Historically, the CVP have been considered as important remedies for maintaining health, enhancing overall immune status, and prevention and treatment of chronic diseases (Ng, 1998). Presently, CVP is considered as a potential candidate for drug development in treatment and prevention of human cancers because of its immunological properties as well as its ability to distinguish cancerous cells from normal cells. Based on a statistics and analysis of anti-tumor plant drugs in a hospital of Guangdong province, the frequency of using CVP is the highest in various fungal polysaccharides during the years of 2000-2002 (Liu et al., 2005). *In vitro* studies reveal that PSP acts selectively on B-cell lymphoma cell line (Raji), human promyelocytic leukemia cell lines (HL-60, NB-4) (Lau et al., 2004; Hsieh et al., 2002), human breast cancer cell lines (T-47D, MCF-7, MDA-MB-231) (Aoyagi et al., 1997; Chow et al., 2003), prostate cancer cell lines (PC-3, DU-145) (Hsieh and Wu, 2001). Although the CVP suppress proliferation of many human cancer cell lines *in vitro* and *in vivo*, not all cancers seem to respond to *C. versicolor* polysaccharopeptides. Normal lymphocytes, human normal liver cell line (WRL) and human breast cancer cell line (BT20) are not affected by PSP (Hsieh et al., 2002; Lau et al., 2004; Ho et al., 2005). The anti-tumor activity of the extract from *C. versicolor* appears to depend on the strains-derived (Yang et al., 2000), the habitat in which it grows (Monro, 2003), the source material (Matsunaga et al., 1996) and the method of recovery used (Chen et al., 2003). The CVP can be produced from *C. versicolor* mushrooms harvested in the wild or cultivated commercially or from mycelial growth of *C. versicolor* in submerged fermentation. The polysaccharopeptides isolated from different sources (mushroom, mycelium, and biomass-free broth) differ somewhat in structure, composition, and physiological activity. The present study aimed to examine the *in vitro* cytotoxic activities of a culture-grown of *C. versicolor* hot-water extract in eight cell lines and to verify if the crude CVP can be extracted from the fruit body. This study provides a method of extract prepared CVP from cultivated fruit bodies, and farther revealed that the CVP significantly suppressed the proliferation of four human breast cancer cells in a dose-dependent manner, and four human liver cancer cells in a selectively manner *in vitro*.

MATERIALS AND METHODS

Reagents

The cells used were human liver cancer cell lines (7703, HepG2, 7721, PLC), human breast cancer cell lines (Bcap37, ZR75-30, MCF-7, T-47D) and human normal liver cell line (WRL) provided by the Cancer Institute of Shanghai Jiao Tong University. The RPMI-1640 medium and fetal calf serums were purchased from the Gibco Laboratories (Grand Island, NY, USA). The MTT (3-(4, 5-dimethylthiazolyl)-2, 5-diphenyl-tetrazolium bromide) and the dimethyl sulfoxide (Me₂SO) were purchased from Sigma Chemical Co. (St. Louis, MO, USA). Other chemicals used were reagent grade which were purchased from local chemical agent store.

Preparation of *C. versicolor* extract

C. versicolor fruiting bodies were cultivated by Shaanxi Key Laboratory of Bio-Resources, Shaanxi University of Technology (Zhou and Lin, 1999). The polysaccharides were obtained from the cultivated fruit bodies. The crude polysaccharide was extracted according to the method described as follows: the fruiting bodies were selected, cleaned, quantified and crushed. Based on a Soxhlet extraction method with petroleum ether as the extractive solvent, the materials was degreased, the residual was air-dried, and then extracted with hot-water at proper proportion and temperature. After being filtrated and discolored, the solution was concentrated to 10% of its original volume using reduced pressure method, followed by precipitation with 95% ethanol. The free proteins and pigment of the extracts were removed by Sevage method and active carbon, and then the extract was refined. The major components of the extract are polysaccharides, the amount of which were measured and extracting rate was calculated by following formula:

$$\text{Polysaccharides extracting rate} = \frac{\text{Dry-weight of ethanol sediments}}{\text{Dry-weight of fruit bodies}}$$

The experiment was replicated three times (Tian et al., 2003).

Determination of polysaccharide content

The contents of polysaccharides were measured by the phenol-sulphuric acid method using glucose as standard (Cuesta et al., 2003). The basic protocol was followed, with the modifications indicated below. The sugar solution (2 ml) and the phenol solution (2 ml) were added to each screw cap tube (18 × 180 mm), which was capped and vortex-stirred. Then 10 ml of concentrated sulfuric acid was added slowly down along the side of the tube. The tubes were then closed, vortex-stirred for 5 s and incubated for 2 min at 100°C water bath. All tubes were allowed to cool down to room temperature before measuring the absorbance at 490 nm using distilled water as blank in the Multiskan Spectrum Microplate Spectrophotometer (Thermo Labsystem).

Cytotoxicity assays

Cells were maintained as monolayer cultures in RPMI-1640 medium supplemented with 10% fetal calf serum and incubated at 37°C in a humidified incubator at 5% CO₂. Toxicity tests were described as before (Campling et al., 1991), nine sorts of cells were seeded independently in 96-well plate with the final volume 100 μ l containing 1 × 10⁴ cells per well. The plates were incubated at 37°C for 48 h. CVP in PBS was proportionally diluted with RPMI-1640, and 50 μ l of each solution was added to triplicate wells. After 72 h,

0.15 mg (30 μ l of 5 g/l) MTT was added to each well and incubated at 37 °C for a further 4 h. The medium was removed and 100 μ l Me₂SO was added into each well after the plate was shaken thoroughly for 10 min. The absorbance of the samples was measured at 570 nm with a Multiskan Spectrum Microplate Spectrophotometer (Thermo LabSystem).

RESULT AND DISCUSSION

Extracting and determining of CVP

With hot-water extraction and ethanol precipitation, the content of the resulting extract (crude polysaccharide) from *C. versicolor* fruit body is about 7.74%. After free proteins and pigment being removed, the extract was refined. The content of purified polysaccharide from extract sample was determined as 54.69%. These results were consistent with previous studies (Tian et al., 2003). The glucose was used as standard to determine content of polysaccharide in the refined extracts. The results showed that linear concentrations, regression equation and regression coefficient were 0~180 μ g/ml, $y = 0.115 + 1.337X$, $R^2 = 0.99867$ respectively. CVP is commonly recovered by precipitation from the concentrated extract. Ethanol precipitation (Tian et al., 2003; Kim et al., 2001) and ammonium sulfate fractionation are used frequently. Conventional ion exchange chromatography on DEAE Sephadex and DEAE cellulose, and advanced HPLC methods have also been used effectively in the final recovery stages to purify CVP, but those are generally impractical in large-scale processing (Cui and Chisti, 2003). However, considering any commercial production process, the number of individual steps in the product recovery train should be kept to a minimum. Then, we select a simple and economic process for recovering CVP and determining the content of polysaccharide in the extracts, which is more practical.

Effects of CVP on the cytotoxicity of human cancer cells

As other fungal-derived bioactive polysaccharides, the CVP also inhibited proliferation of intact cells (Chang, 2002; Ebina, 2003). The CVP inhibited the proliferation of cancer cells of 7703, Bcap37, T-47D in low concentration; the IC₅₀ of CVP on 7703, Bcap37, and T-47D were 18.37, 14.42 and 9.29 mg/l, respectively. The CVP also inhibited the proliferation of cancer cells of MCF-7 and ZR75-30, but at high concentration, the IC₅₀ of CVP on MCF-7 and ZR75-30 were 39.26 and 34.59 mg/l (Figure 1). The CVP does not inhibit the proliferation of cancer cells of HepG2, 7721, PLC and human normal liver cell line (WRL). The study results show that the CVP can selectively and dose-dependently inhibit the proliferation of four breast cancer cell lines, with ascending order of IC₅₀ values: T-47D, Bcap37, ZR75-30, MCF-7, while it can only inhibit the proliferation of one liver cancer cell line (7703). Three




Figure 1. Determination of antitumor activity and cytotoxicity of CVP on one human liver cancer cell lines (7703) and four human breast cancer cell lines (ZR75-30, Bcap37, MCF-7, T-47D).

human liver cancer cell lines (HepG2, 7721, PLC) and human normal liver cell line (WRL) are not affected by CVP. This result suggests that CVP is more actively in the inhibition of proliferation of human breast cancer cells than human liver cancer cell cells. The CV extract can selectively suppress the proliferation of various cell and cell lines are consistent with previous reports (Lau et al., 2004; Ho et al., 2005). The recent studies demonstrated the *in vitro* anticancer mechanism(s) of CVP which include retardation of cancer proliferation by delaying cell cycle and induction of apoptosis in breast and cervical tumor cell lines, as well as leukemia and lymphoma cell lines (Ho et al., 2005). Previous research reports that CVP at 50 to 800 μ g/ml dose-dependently suppressed the proliferation of B-cell lymphoma (Raji) and human promyelocytic leukemia (HL-60, NB-4) cell lines by more than 90% ($p < 0.01$), with ascending order of IC₅₀ values: HL-60 (147.3 g/l), Raji (253.8 g/l) and NB-4 (269.3 g/l). The CVP was found to selectively and dose-dependently inhibit the proliferation of lymphoma and leukemic cells possibly via an apoptosis-dependent pathway (Lau et al., 2004). Another research found out that the CVP dose-dependently suppressed the proliferation of three breast tumor cell lines, T-47D, MCF-7, MDA-MB-231, while BT-20 cells were not significantly affected (Ho et al., 2005). The anti-proliferative effects of the CVP on MDA-MB-231, MCF-7 and T-47D cells are mediated through apoptosis induction, which in turn is differentially regulated depending on p53 and Bcl-2 expression. The CVP significantly suppressed the proliferation of T-47D cell via up-regulation of the p53 protein expression and down-regulation of Bcl-2 protein expression, but in MCF-7 cell it is via down-regulation Bcl-2 protein expression only. But the expression of p53 and Bcl-2 protein are unaffected in

MDA-MB-231 cell treated with CVP. The study results further support the contention that CVP selectively inhibits the tumor cell growth. The mechanism of action of the selective effect of CVP causing tumor cell death may involve different parameters of apoptosis.

ACKNOWLEDGEMENTS

The authors wish to thank Qi Fei (PhD) (Tumor Research Institute, Shanghai Jiaotong University, Shanghai, China) for their help on the proliferation of human cancer cell lines. Also we express our thanks to the Technologists in the Shaanxi Key Lab. of bio-resources (Shaanxi University of Technology, Shaanxi, China) for their support on the extraction of CVP. This research is financially supported by the School of Agriculture and Biology, Shanghai Jiaotong University.

REFERENCES

- Aoyagi H, Lino Y, Takeo T, Horii Y, Morishita Y, Horiuchi R (1997). Effects of OK-432 (picibanil) on the estrogen receptor of MCF-7 cells and potentiation of antiproliferative effects of tamoxifen in combination with OK-432. *Oncology* 54: 414-423.
- Campling BG, Pym J, Baker HM, Cole SP, Lam YM (1991). Chemosensitivity testing of small cell lung cancer using the MTT assay. *Br. J. Cancer* 63: 75-83.
- Chang R (2002). Bioactive polysaccharides from traditional Chinese medicine herbs as anticancer adjuvants. *J. Altern. Complement. Med.* 8: 559-565.
- Chen WX, Lu Y, Wang AW, Yang B (2003). Comparison of antitumor effects of Ganoderma polysaccharides extracted with different extraction process. *J. Nanjing Univ. Tradit. Chin. Med: Nat. Sci.* 19: 227-228.
- Chow LW, Lo CS, Loo WT, Hu XC, Sham JS (2003). Polysaccharide peptide mediates apoptosis by up-regulating p21 gene and down-regulating cyclin D1 gene. *Am. J. Chin. Med.* 31: 1-9.
- Chu KK, Ho SS, Chow AH (2002). *Coriolus versicolor*: a medicinal mushroom with promising immunotherapeutic values. *J. Clin. Pharmacol.* 42: 976-984.
- Cuesta G, Suarez N, Bessio MI, Ferreira F, Massaldi H (2003). Quantitative determination of pneumococcal capsular polysaccharide serotype 14 using a modification of phenol-sulfuric acid method. *J. Microbiol. Methods* 52: 69-73.
- Cui J, Chisti Y (2003). Polysaccharopeptides of *Coriolus versicolor*: physiological activity, uses, and production. *Biotechnol. Adv.* 21: 109-122.
- Ebina T (2003). Activation of antitumor immunity by intratumor injection of biological preparations. *Gan To Kagaku Ryoho.* 30: 1555-1558.
- Ho CY, Kim CF, Leung KN, Fung KP, Tse TF, Chan H, Lau CB (2005). Differential antitumor activity of *Coriolus versicolor* (Yunzhi) extract through p53- and/or Bcl-2-dependent apoptotic pathway in human breast cancer cells. *Cancer Biol. Ther.* 4(6): 638-644.
- Hsieh TC, Kunicki J, Darzynkiewicz Z, Wu JM (2002). Effects of extracts of *Coriolus versicolor* (Im-Yunity) on cell-cycle progression and expression of interleukins-1 beta,-6, and -8 in promyelocytic HL-60 leukemic cells and mitogenically stimulated and nonstimulated human lymphocytes. *J. Altern. Complement. Med.* 8: 591-602.
- Hsieh TC, Wu JM (2001). Cell growth and gene modulatory activities of Yunzhi (Windsor Wunxi) from mushroom *Trametes versicolor* in androgen-dependent and androgen-insensitive human prostate cancer cells. *Int. J. Oncol.* 18: 81-88.
- Kim DH, Yang BK, Jeong SC, Park JB, Cho SP, Das S, Yun JW, Song CH (2001). Production of a hypoglycemic, extracellular polysaccharide from the submerged culture of the mushroom. *Phellinus linteus*. *Biotechnol. Lett.* 23: 513-517.
- Lau CB, Ho CY, Kim CF, Leung KN, Fung KP, Tse TF, Chan HH, Chow MS (2004). Cytotoxic activities of *Coriolus versicolor* (Yunzhi) extract on human leukemia and lymphoma cells by induction of apoptosis. *Life Sci.* 75: 797-808.
- Liu Y, Ren B, Wu AQ, Li SX, Fu XH (2005). Analysis on antitumor plant medicine in Guangdong province. *Guangdong Pharm. J.* 15: 51-54.
- Matsunaga K, Oguchi Y, Ohara M (1996). Aglycoprotein ligand for platelet-derived growth factor and transforming growth factor β from *Coriolus*. EP: 702028 (CA 1997, 124: 333064m).
- Monro JA (2003). Treatment of cancer with mushroom products. *Achiv. Environ. Health* 58(8): 533-537.
- Ng TB (1998). A review of research on the protein-bound polysaccharide (Polysaccharopeptide. PSP) from the mushroom *Coriolus versicolor* (Basidiomycetes: Polyporaceae). *Gen. Pharmacol.* 30: 1-4.
- Tian GH, Meng JL, Xu YH (2003). Study on polysaccharides extraction and determination from wild and growing *Polystictus versicolor* fruit bodies. *J. Hanzhong Teach. Coll. (Nat. Sci.)* 21: 68-72.
- Wang HX, Ng TB, Liu WK, Ooi VE, Chang ST (1996). Polysaccharide-peptide complexes from the cultured mycelia of the mushroom *Coriolus versicolor* and their culture medium activate mouse lymphocytes and macrophages. *Int. J. Biochem. Cell Biol.* 28: 601-607.
- Yang XT, Mi K, Feng HQ, Wu YC, Yang QY (2000). Comparison of polysaccharopeptides from different strains of *Coriolus versicolor* and with different extractive methods. *Chin. J. Pharm.* 31: 545-548.
- Zhang JS, Han WW, Pan YJ (2001). Studies on chemical structure of polysaccharide from fruit body of *Coriolus versicolor*. *Acta Pharm. Sin.* 36: 664-667.
- Zhou XW, Lin J (1999). Biological characteristics and cultivation techniques of *Coriolus versicolor*. *Quart. Forest By-prod. Speciality China* 4: 23-24.